Gibson Dunn
Ryan Murr
- Deals
- 7
- Latest
- Sep 2026
- Most deals in
- Biotech
Firm
- Gibson Dunn Law firm · 2026 · 7 deals
Often works with
- Branden Berns 6 deals together
- Evan Shepherd 3 deals together
- Dirk Oberbracht 1 deal together
- Sonja Ruttmann 1 deal together
- Aliresa Fatemi 1 deal together
- Simon Stöhlker 1 deal together
- Andreas Rief 1 deal together
- Tim Windfelder 1 deal together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Sep 2026 | Aethlon Medical | – | – | Merger | Legal adviser to North Immunology | Announced | – | Biotech | North Immunology and Aethlon Medical merger |
| Jul 2026 | Avere Therapeutics | – | – | Placement | Legal adviser to the issuer | Announced | 320.0 | Biotech+1 | Avere Therapeutics placement |
| Jul 2026 | Avere Therapeutics | – | NextCure | Merger | Legal adviser to Avere Therapeutics (target) | Announced | – | Biotech+1 | NextCure and Avere Therapeutics merger |
| May 2026 | Mentari Therapeutics | – | – | Placement | Legal adviser to the issuer | Announced | 290.0 | Biotech+1 | Mentari Therapeutics placement |
| May 2026 | Orphai Therapeutics | – | Quince Therapeutics | Acquisition | Legal adviser to LifeSci Capital (acquirer) | Completed | – | Biotech+2 | Quince Therapeutics acquisition of Orphai Therapeutics |
| Apr 2026 | US sales and distribution rights for seven Assertio branded products | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Legal adviser to Assertio Holdings (seller) | Announced | – | Pharma | Cosette Pharmaceuticals acquisition of US sales and distribution rights for seven Assertio branded products |
| Feb 2026 | AiCuris Anti-infective Cures AG | – | Veloxis Pharmaceuticals | Acquisition | Legal adviser to shareholders (target) | Announced | 913.0 | Pharma+1 | Veloxis Pharmaceuticals acquisition of AiCuris Anti-infective Cures AG |
Deals where Ryan Murr is named on the firm's deal team, by the firm or the press.